Healthcare
Geron Corporation(GERN)
Live Price
Offline$1.26
+2.44% today
1Y Change
-8.88%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $980.00M
- Revenue Growth
- +138.8%
- EPS Growth
- +51.9%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Geron Corporation (GERN) is a Healthcare stock with a market cap of $980.00M and listed on NASDAQ. The stock last traded around $1.26 and down 8.9% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +138.8%, EPS growth of +51.9%, a dividend yield of 0.0%. What stands out right now is revenue +138.8%, EPS +51.9%, free cash flow +49.3% with operating margin -29.3% and ROIC -11.3%. Valuation sits in the middle of the pack at price/sales 5.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GERN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+138.8% vs +7.6% peer median
Operating Margin
Below sector median
-29.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +138.8% and EPS at +51.9%, with operating margin around -29.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -7.6% | -10.8% | -23.4% |
2026 Feb 25, 2026 | +0.0% | -4.1% | -14.5% | -8.7% |
2025 Nov 5, 2025 | +18.2% | -0.9% | +13.8% | +16.5% |
Benchmark Edge
GERN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GERN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GERN Max Drawdown
-43.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GERN and SPY.
Company Overview
Geron Corporation
NASDAQ Global Select
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
- Leadership
- Harout Semerjian
- IPO Date
- Jul 31, 1996
- Employees
- 229
- Street Address
- 919 East Hillsdale Boulevard
- Mailing
- Foster City, CA, 94404
- Region
- Foster City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 473 7700
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.4
- Price/Book
- 4.5
Growth
- Revenue
- +138.8%
- EPS
- +51.9%
- Free Cash Flow
- +49.3%
Profitability
- Gross Margin
- 86.0%
- Operating Margin
- -29.3%
- Net Margin
- -46.7%
- ROE
- -34.2%
- ROIC
- -11.3%
Balance Sheet
- Debt/Equity
- 1.11
- Current Ratio
- 4.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.